Completed study

Official Study Title
A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab

Brief Description
LIGHT is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully humanized antibody targeting interleukin-1alpha, over placebo for patients with systemic sclerosis.

Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 2 sites in Greece
Actual enrolment: 20 participants Identifier: NCT04045743
EudraCT number: 2018-004655-20
National Organization for Medicines Approval: IS008-19
National Ethics Committee Approval: 9/19

Study Start: July 2019
Study Completion: July 2021

Condition/Disease studied: Scleroderma; Systemic